We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

New Options for Preoperative Anesthesia in Intrauterine Needling (NO PAIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01013558
Recruitment Status : Completed
First Posted : November 13, 2009
Last Update Posted : December 8, 2009
Leuven University Medical Center
Information provided by:
Leiden University Medical Center

November 10, 2009
November 13, 2009
December 8, 2009
September 2004
December 2007   (Final data collection date for primary outcome measure)
evidence of fetal stress response by changes in fetal stress hormones beta-endorphin, noradrenalin and cortisol [ Time Frame: 15-60 minutes ]
Same as current
Complete list of historical versions of study NCT01013558 on ClinicalTrials.gov Archive Site
influence of analgesics (remifentanil) on the fetal stress response [ Time Frame: 15-60 minutes ]
Same as current
Not Provided
Not Provided
New Options for Preoperative Anesthesia in Intrauterine Needling
NO PAIN: New Options for Preoperative Anesthesia in Intrauterine Needling
The concept of fetal pain is becoming increasingly relevant due to growing possibilities for invasive intrauterine treatment. There is much debate as to whether the fetus is mature enough to be able to perceive pain at all. Recent studies have suggested that the fetus is at least capable of exhibiting a stress response to intrauterine needling. Intrauterine transfusions are most commonly performed by inserting a needle either in the umbilical cord root at the placental surface, or in the intrahepatic portion of the umbilical vein of the fetus. Recently, intrauterine needling in the intrahepatic vein has been shown to result in alterations in fetal stress hormones, which has been interpreted as a reaction to pain. These changes were not observed in intrauterine needling in the umbilical cord root, or after administration of analgesics to the fetus. The investigators tested the hypothesis that remifentanil provides fetal analgesia, assessed by a reduced fetal stress response. The investigators performed a randomised controlled trial comparing fetal stress response between patients undergoing intrauterine transfusions for alloimmune fetal anemia receiving remifentanil, or placebo.
Not Provided
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
  • Stress
  • Pain
  • Drug: Remifentanil
    0.15 microgram/kg/min continuous infusion.
  • Drug: saline
    continuous infusion
  • Active Comparator: remifentanil
    Intervention: Drug: Remifentanil
  • Placebo Comparator: saline
    Intervention: Drug: saline
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2007
December 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • singleton pregnancy
  • clinically indicated intrauterine transfusion
  • red cell alloimmunisation

Exclusion Criteria:

  • severe adipositas
  • suspicion of structural anomalies
  • fetal hydrops
  • contraindication for remifentanil
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
F.P.H.A. Vandenbussche, MD PhD, Leiden University Medical Center
Leiden University Medical Center
Leuven University Medical Center
Principal Investigator: Frank P.H.A. Vandenbussche, MD PhD Leiden University Medical Center
Leiden University Medical Center
November 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP